CytomX Therapeutics (CTMX) Assets Average (2015 - 2026)
CytomX Therapeutics' (CTMX) quarterly Assets Average came in at $255.5 million in Q1 2026, up 133.27% YoY from $109.5 million in Q1 2025, and up 64.91% on a QoQ basis from $154.9 million in Q4 2025.
CytomX Therapeutics (CTMX) Assets Average (2015 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 12 years of Assets Average data on file, last reported at $255.5 million in Q1 2026.
- Quarterly Assets Average rose 133.27% year-over-year to $255.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255.5 million (up 133.27% YoY) and the FY2025 annual result came in at $136.0 million, down 15.58% from the prior year.
- Assets Average climbed to $255.5 million in Q1 2026, from $154.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $318.1 million in Q1 2022 to a low of $109.5 million in Q1 2025.
- A 5-year average of $202.8 million and a median of $211.5 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average sank 43.33% — and 2026, when it surged 133.27%.
- Tracing CTMX's Assets Average over 5 years: stood at $243.7 million in 2022, then retreated by 13.22% to $211.5 million in 2023, then tumbled by 38.64% to $129.8 million in 2024, then climbed by 19.38% to $154.9 million in 2025, then jumped by 64.91% to $255.5 million in 2026.
- The last three Assets Average figures came in at $255.5 million (Q1 2026), $154.9 million (Q4 2025), and $166.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 370.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 370.29 Mn |
| Mar 31, 2026 | 255.46 Mn |
| Dec 31, 2025 | 154.91 Mn |
| Sep 30, 2025 | 166.66 Mn |
| Jun 30, 2025 | 136.78 Mn |
| Mar 31, 2025 | 109.52 Mn |
| Dec 31, 2024 | 129.76 Mn |
| Sep 30, 2024 | 149.10 Mn |
| Jun 30, 2024 | 171.95 Mn |
| Mar 31, 2024 | 193.24 Mn |
| Dec 31, 2023 | 211.48 Mn |
| Sep 30, 2023 | 215.18 Mn |
| Jun 30, 2023 | 221.91 Mn |
| Mar 31, 2023 | 247.76 Mn |
| Dec 31, 2022 | 243.69 Mn |
| Sep 30, 2022 | 243.29 Mn |
| Jun 30, 2022 | 278.46 Mn |
| Mar 31, 2022 | 318.12 Mn |
| Dec 31, 2021 | 355.32 Mn |
| Sep 30, 2021 | 386.84 Mn |